89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

89bio, Inc. (Nasdaq: ETNB) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting September 13 at 7:00 a.m. ET via the H.C. Wainwright conference portal. An archived webcast will be accessible on 89bio’s website. 89bio focuses on innovative therapies for liver and cardio-metabolic diseases, with its lead product candidate, BIO89-100, targeting nonalcoholic steatohepatitis and severe hypertriglyceridemia.

News Market Reaction – ETNB

+0.26%

+0.26% Session move

In the trading session that priced this news, ETNB gained 0.26%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in the H.C. Wainwright 23^rd Annual Global Investment Conference to be held September 13-15, 2021.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021. An archived webcast will also be accessible in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com

FAQ

What event will 89bio, Inc. participate in September 2021?

89bio, Inc. will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

When does the presentation at the H.C. Wainwright conference start?

The presentation will start on September 13, 2021, at 7:00 a.m. ET.

Where can I access the 89bio conference presentation?

The presentation will be available on-demand through the H.C. Wainwright conference portal and archived on 89bio’s website.

What is the lead product candidate of 89bio, Inc.?

The lead product candidate of 89bio, Inc. is BIO89-100, which targets nonalcoholic steatohepatitis and severe hypertriglyceridemia.

What is the focus area of 89bio, Inc.?

89bio, Inc. focuses on the development of therapies for liver and cardio-metabolic diseases.